SEOUL, Aug. 4 (UPI) -- A group of scientists, primarily from South Korean universities, has confirmed the efficacy of an oral anti-viral treatment, called CP-COV03 or Xafty, against COVID-19 after a clinical trial. If a later-stage trial is successful and the medication is approved by the Ministry of Food and Drug Safety, the drug could be available next year. Developed by Korea's biotech company Hyundai Bioscience, the drug was found to address major COVID-19 symptoms listed by the U.S. Food

Tag-uri: Coronavirus